Use of Focalin for Fatigue in Sarcoidosis
Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects.
1 other identifier
interventional
12
1 country
1
Brief Summary
Patients diagnosed with chronic sarcoidosis with fatigue for more than 6 months. Sarcoidosis and its treatment can greatly affect your quality of life. Many patients suffer from fatigue (feeling tired), lack of focus and concentration, in ability to organize their daily activities, and memory loss. These commonly reported symptoms often get in the way of everyday life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Jun 2006
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2006
CompletedFirst Submitted
Initial submission to the registry
August 7, 2006
CompletedFirst Posted
Study publicly available on registry
August 8, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2008
CompletedFebruary 24, 2011
February 1, 2011
1 year
August 7, 2006
February 23, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Improvement of fatigue.
30 weeks
Secondary Outcomes (2)
Improvement of pulmonary status
30 weeks
Safety of treatment
30 weeks
Interventions
oral dosing for 8 weeks then cross over to placebo in random order
Eligibility Criteria
You may qualify if:
- Diagnosis of sarcoidosis using standard criteria
- Disease for more than one year
- Complain of fatigue which has been present for more than six months.
- Over 18 years of age
You may not qualify if:
- Pregnancy
- Change in therapy for sarcoidosis in prior three months
- history of ventricular arrythmias
- Patients with a history of anxiety disorder, glaucoma, motor ties or a family history of Tourette's syndrome.
- Patients who are currently receiving or have received monoamine oxidase inhibitors within 14 days prior to study entry.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Cincinnati Medical Center
Cincinnati, Ohio, 45267-0565, United States
Related Publications (1)
Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008 May;133(5):1189-95. doi: 10.1378/chest.07-2952. Epub 2008 Feb 8.
PMID: 18263672DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Robert P Baughman, MD
Unversity of Cincinnati
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 7, 2006
First Posted
August 8, 2006
Study Start
June 1, 2006
Primary Completion
June 1, 2007
Study Completion
January 1, 2008
Last Updated
February 24, 2011
Record last verified: 2011-02